Prenatal screening refers to a set of tests done during pregnancy—using ultrasound, a maternal blood draw, and other low-risk methods—to estimate how likely it is that a fetus has a common chromosomal abnormality, most notably trisomy 21 (Down syndrome). NT (nuchal translucency) ultrasound, the maternal serum screening (often called the “combined test” or “quad screen”), and NIPT (non-invasive prenatal testing) are the three most common screening options in the first and second trimesters. All three are screening, not diagnosis: they give a risk probability, whereas a definitive answer requires a diagnostic test such as amniocentesis or chorionic villus sampling (CVS). Understanding how each works, the best timing, accuracy, and limitations helps expectant parents and clinicians make evidence-based decisions and reduces unnecessary anxiety.
What prenatal screening is: the role of NT, serum screening and NIPT
A typical human cell has 23 pairs of chromosomes, 46 in total. When an extra copy is present—trisomy 21 (an extra chromosome 21), trisomy 18, or trisomy 13—it can cause developmental delay, intellectual disability, and multiple malformations. Trisomy 21, or Down syndrome, is the most common. The goal of prenatal screening is to estimate risk without harming the fetus, and then decide whether an invasive diagnostic test is needed. NT, serum screening, and NIPT are all screening tools; they differ mainly in how they are performed, when, and how accurately.
NT (nuchal translucency) ultrasound
NT stands for nuchal translucency—the fluid-filled space at the back of the fetal neck, measured in early pregnancy by transvaginal or abdominal ultrasound. In a healthy fetus this thickness increases slightly with gestational age; an excessive measurement is associated with trisomy 21, 18, and 13, as well as some congenital heart defects.
- Timing: between 11 weeks and 13 weeks + 6 days, and most accurate when the crown-rump length is 45–84 mm.
- Method: ultrasound, completely non-invasive, usually 10–20 minutes.
- Accuracy: NT alone detects about 70%–80% of trisomy 21 cases, with a false-positive rate around 5%; combined with maternal serum markers, detection improves further.
- Note: results depend heavily on the sonographer’s experience and equipment; use a qualified facility.
Maternal serum screening (the “quad screen”)
Serum screening measures specific biochemical markers in the mother’s blood (such as free β-hCG, PAPP-A, AFP, uE3, and inhibin A), then combines them with gestational age, maternal age, weight, and whether the pregnancy is from IVF to calculate a risk score. It is offered as first-trimester screening (11–13⁺⁶ weeks, often with NT) or second-trimester (15–20⁺⁶ weeks).
- First-trimester: combined with NT, detects about 85%–90% of trisomy 21.
- Second-trimester: alone detects about 60%–70% of trisomy 21, false-positive around 5%.
- Pros: low cost, widely available, usually part of routine care, and reimbursed in many regions.
- Cons: less accurate than NIPT; affected by weight, twins, IVF, and dating errors.
Non-invasive prenatal testing (NIPT)
NIPT draws a maternal blood sample and analyzes cell-free fetal DNA (cffDNA, released from the placenta) using high-throughput sequencing to check for extra or missing chromosomes. It is generally offered from 12 weeks (some kits from 10 weeks).
- Accuracy: detects over 99% of trisomy 21, with a false-positive rate below 0.1%–1%; also detects most trisomy 18 and 13; detection of sex-chromosome and microdeletion conditions varies by kit.
- Pros: a simple blood draw—non-invasive and safe—with far higher accuracy than serum screening, and available earlier.
- Cons: still a screening test; a positive result must be confirmed by diagnostic testing; interpretation is limited in twins, mosaicism, or recent transplant; cost is higher.
Core differences at a glance
| Item | NT ultrasound | Serum screening | NIPT |
|---|---|---|---|
| Method | Ultrasound of nuchal fluid | Maternal blood markers | cfDNA sequencing from blood |
| Best window | 11–13⁺⁶ weeks | 1st trim 11–13⁺⁶; 2nd 15–20⁺⁶ | Usually ≥12 weeks |
| Main targets | T21/T18/T13, heart defects | T21/T18 risk | T21/T18/T13, some sex & microdeletion |
| T21 detection | ~70%–80% | ~60%–70% (higher combined) | >99% |
| False positive | ~5% | ~5% | <0.1%–1% |
| Non-invasive | Yes | Yes | Yes |
| Cost / cover | Usually in package | Often reimbursed / low cost | Mostly self-pay, some regions covered |
| Main limit | Operator-dependent | Lower accuracy, easily affected | Positive needs confirmation; twins limited |
How to choose by gestational age and risk level
Most expectant parents can follow this logic, but the final plan should be decided with the obstetrician:
- All pregnancies: complete NT at 11–13⁺⁶ weeks (with first-trimester serum if available) as baseline screening.
- Average-risk: NT + second-trimester serum, or NIPT directly if affordable for higher accuracy.
- Advanced maternal age (≥35), prior affected pregnancy, or family history: consult a prenatal diagnosis clinic; amniocentesis may be offered even after NIPT.
- Twins: NT is still useful; NIPT interpretation is limited—decide after genetic counseling.
- IVF / mosaicism / special cases: tell your doctor, as some screening accuracy drops.
Individual circumstances vary greatly; please follow the professional advice of your doctor or genetic counselor.
What if a screening result is abnormal
Importantly, a “high-risk” screen does not mean the baby is affected, and “low-risk” does not guarantee a normal result. If high risk is indicated, next steps may include rechecking dates and details, repeating NIPT if appropriate, genetic counseling, and considering amniocentesis or CVS. Diagnostic tests carry a small miscarriage risk (amniocentesis about 0.1%–0.5%, depending on experience); your doctor will discuss the trade-offs with you.
Key points: NT, serum screening, and NIPT are screening, not diagnosis; NT falls at 11–13⁺⁶ weeks, serum splits into first/second trimester, NIPT is usually ≥12 weeks with the highest accuracy; any positive result needs diagnostic confirmation; the choice should fit gestational age, maternal age, risk level, and medical advice.
Related topics
- 妊娠糖尿病饮食指南
- 叶酸什么时候吃
- 产后42天复查清单
